Pre-seed open · 12 months to first market
AVIX Pharmaceuticals Limited · United Kingdom & Bangladesh
Roadmap
Twelve months to first sale. Four years to a moat.
Two regulatory routes with very different timescales, run deliberately in parallel so the fast one funds and de-risks the slow one.
01 ·The next twelve monthsQuarter by quarter.
Every item is fundable, measurable and dated. Nothing here depends on an approval we do not control.
Q1 · Intellectual property
Priority patent applications filed on lead combinations
The first use of funds. Until priority applications exist the combinations are unprotected and the company is hard to value. Filing also unlocks the scientific disclosure needed for partnership discussions.
Q1 · Laboratory
MIC panel across an expanded isolate set; serial-passage protocol agreed
Converts screening data into the characterisation data regulators and partners recognise. Serial passage answers the central scientific question: does resistance develop more slowly against a three-target combination?
Q2 · Regulatory
Classification confirmed with advisers in Bangladesh, UK and EU
Determines dossier scope and what may lawfully be claimed in each market. Whether the product is a feed material, a zootechnical additive or a veterinary medicine changes cost, timeline and value materially.
Q2–Q3 · In-vivo
Controlled broiler study: efficacy, feed conversion, mortality, safety, residues
The single result that determines whether this becomes a product. Designed to EFSA data standards so the same study serves both regulatory tracks rather than being repeated later at full cost.
Q3 · Manufacture
CMO batches produced; potency assay and stability programme running
Batch-to-batch consistency is this category's documented failure mode. Botanical potency varies with growing conditions, harvest and extraction, so a validated potency assay is a competitive asset in itself.
Q3–Q4 · Commercial
Distribution agreement signed in beachhead market
Converts a laboratory result into a route to a customer.
Q4 · Commercial
First commercial sales on Track A
Revenue, field data, and proof that producers will pay — the three things that change the terms of the next round.
Q4 · Team
Animal-health regulatory and commercial hire
The capability the founding team does not currently have, recruited once there is data worth commercialising.
02 ·Regulatory realityWhy the twelve-month plan is not a European launch plan.
The programme uses two coordinated tracks rather than pretending one regulatory route fits every market.
- Europe takes longer: full safety, efficacy and characterisation are required.23
- Track A: lawful regional entry without therapeutic claims.
- Track B: European evidence is built in parallel.
- One architecture: design studies once to the higher standard.
Programme-design targetBuild once. Reuse evidence wherever regulators permit.
- Classify early · settle classification and claims before pivotal studies.
- Design once · build analytical and stability packages to one standard.23
- Run in parallel · coordinate safety, efficacy and regulatory work.
- Reuse evidence · design poultry data for regional and later EU use.
Programme target: reduce duplicated studies. This is not a guaranteed regulatory timetable.
Scientific references1 source used on this page
23European Food Safety Authority.
European Food Safety Authority. Feed additives application procedure, reviewed May 2026. The application lifecycle covers pre-submission, submission and completeness, risk assessment and post-adoption; dossiers address identity, characterisation, conditions of use, target-animal safety, consumer, user and environmental safety, and efficacy. efsa.europa.eu